Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.

Belli LS, Volpes R, Graziadei I, Fagiuoli S, Starkel P, Burra P, Alberti AB, Gridelli B, Vogel W, Pasulo L, De Martin E, Guido M, De Carlis L, Lerut J, Cillo U, Burroughs AK, Pinzello G.

Dig Liver Dis. 2012 Jul;44(7):603-9. doi: 10.1016/j.dld.2012.01.017. Epub 2012 Mar 15.

PMID:
22424641
2.

The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.

Perrakis A, Yedibela S, Schuhmann S, Croner R, Schellerer V, Demir R, Hohenberger W, Müller V.

Transplant Proc. 2011 Dec;43(10):3824-8. doi: 10.1016/j.transproceed.2011.08.103.

PMID:
22172854
3.

Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.

Dhanasekaran R, Sanchez W, Mounajjed T, Wiesner RH, Watt KD, Charlton MR.

Liver Int. 2015 Nov;35(11):2433-41. doi: 10.1111/liv.12890. Epub 2015 Jul 1.

PMID:
26058570
4.

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X.

Gastroenterology. 2007 May;132(5):1746-56. Epub 2007 Mar 24.

PMID:
17484872
5.

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.

Calmus Y, Duvoux C, Pageaux G, Wolf P, Rostaing L, Vanlemmens C, Botta-Fridlund D, Dharancy S, Gugenheim J, Durand F, Néau-Cransac M, Boillot O, Chazouillères O, Samelson L, Boudjema K, Samuel D.

J Hepatol. 2012 Sep;57(3):564-71. doi: 10.1016/j.jhep.2012.04.022. Epub 2012 May 18.

PMID:
22613001
6.

Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.

Nair S, Lipscomb J, Eason J.

Transplantation. 2008 Aug 15;86(3):418-22. doi: 10.1097/TP.0b013e31817c1543.

PMID:
18698245
7.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

8.

Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.

Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group..

Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12.

9.

Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.

Peribañez-Gonzalez M, da Silva MH, Vilar FC, Seixas-Santos Nastri AC, Ferreira PA, Focaccia R, Mendes Correa MC.

Ann Hepatol. 2013 Mar-Apr;12(2):228-35.

10.

High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.

Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB.

Hepatol Int. 2015 Jan;9(1):76-83. doi: 10.1007/s12072-014-9589-6. Epub 2014 Nov 29.

PMID:
25788382
11.

Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.

Tamè M, Buonfiglioli F, Del Gaudio M, Lisotti A, Cecinato P, Colecchia A, Azzaroli F, D'Errico A, Arena R, Calvanese C, Quarneti C, Ballardini G, Pinna AD, Mazzella G.

World J Gastroenterol. 2013 Aug 28;19(32):5278-85. doi: 10.3748/wjg.v19.i32.5278.

12.

High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.

Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D, Gheorghe C, Iacob R.

J Gastrointestin Liver Dis. 2009 Mar;18(1):51-6.

13.

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Reed A, Hemming A, Howard R, Van Der Werf W, Lauwers G, Liu C, Crawford JM, Davis GL, Nelson DR.

Liver Transpl. 2002 Nov;8(11):1000-6.

14.

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.

Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J.

J Hepatol. 2005 Jul;43(1):53-9. Epub 2005 Apr 11.

PMID:
15876467
15.

Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.

Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH.

Dig Dis Sci. 2015 Feb;60(2):573-81. doi: 10.1007/s10620-014-3361-6. Epub 2014 Sep 19.

PMID:
25236421
16.

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML.

Am J Transplant. 2006 Oct;6(10):2348-55. Epub 2006 Jul 26.

17.

Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.

Kornberg A, Küpper B, Tannapfel A, Thrum K, Bärthel E, Habrecht O, Settmacher U.

Transplantation. 2008 Aug 15;86(3):469-73. doi: 10.1097/TP.0b013e31817c0e20.

PMID:
18698252
18.

Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.

Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S.

Eur J Gastroenterol Hepatol. 2013 Jul;25(7):798-805. doi: 10.1097/MEG.0b013e32835eb8bf.

PMID:
23395996
19.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
20.

Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.

Giordanino C, Sacco M, Ceretto S, Smedile A, Ciancio A, Cariti G, De Blasi T, Picciotto A, Marenco S, Grasso A, Pirisi M, Smirne C, Colletta C, Traverso A, Mazzucco D, Ciccone G, Simondi D, Rizzetto M, Saracco G.

Eur J Gastroenterol Hepatol. 2014 Jan;26(1):52-8. doi: 10.1097/MEG.0b013e328362dc99.

PMID:
23719564

Supplemental Content

Support Center